BIIB logo

BIIB Biogen Inc.

NASDAQ Global Select · Drug Manufacturers - General · Healthcare

$247.13
-4.28 (-1.70%)

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides…

Market Cap: $36.53Bwww.biogen.com

Price

No data yet.

Social Signal Score

52
5d
48
5 mentions
—
30d
54
16 mentions
—
60d
54
32 mentions
—
90d
53
43 mentions
—
rss: 13 · news: 28 · marketaux: 2

Analyst Ratings

49 analysts
Buyconsensus
Strong Buy 0Buy 33Hold 15Sell 1Strong Sell 0
Avg price target$262.65+6.3%
Low $175Median $260High $325
Current Consensus

Revenue

$2.80B-2.36%
$2.28B$2.75B$3.21B$3.68B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$14.94
$14.62–$15.56
29 analysts
FY2026
$12.51-16% YoY
$12.07–$13.08
20 analysts
FY2027
$16.23+30% YoY
$8.66–$19.01
21 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Christopher A. Viehbacher
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
7,500
Beta
0.17
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
3.15
www.biogen.com